ArticleClinicoEconomics and outcomes research : CEOR2025
Cost-Effectiveness Analysis and Priority Setting in the Transition from Iron-Folic Acid (IFA) to Multiple Micronutrient Supplementation (MMS) for Pregnant Women in Indonesia.
Article in ClinicoEconomics and outcomes research : CEOR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The World Health Organization (WHO) has advocated for multiple micronutrient supplementation (MMS) for pregnant women since 2016 to mitigate the risk of various complications. As a country considering investment in MMS, Indonesia requires an assessment of the cost-effectiveness analysis and priority setting in the transition from IFA to MMS, which is essential in the decision-making process. Methods: An open-access online modelling tool was used to estimate the cost-effectiveness of MMS (ICERs per DALY averted) at national and sub-national levels (38 provinces) in Indonesia. The results were then prioritized via a cost-effectiveness league table, with a deterministic sensitivity analysis testing the robustness of the results. Results: Implementing MMS under 44% and 100% coverage scenarios has the potential to avert 54,897 and 124,766 DALYs in Indonesia, respectively, and produced an equivalent incremental cost-effectiveness ratio (ICER) value of USD 10 per DALY averted, which is regarded as highly cost-effective. Since costs and benefits scale linearly with coverage, ICER per DALY averted stays unchanged. The MMS program is recommended to be prioritized in 18 provinces having favorable ICERs, which are Southwest Papua, Highlands Papua, Bali, West Java, South Kalimantan, North Maluku, West Papua, Aceh, North Sumatra, Central Java, Central Kalimantan, West Sulawesi, Maluku, Yogyakarta, East Java, North Kalimantan, South Sulawesi, and South Papua. Related to the sensitivity analysis, the cost of MMS and IFA are the most significant variables influencing the ICER value. Conclusion: The findings show that the implementation of MMS, in comparison to IFA, produces a highly cost-effective outcome in 44% and 100% scenarios. The MMS implementation strategy may initiate with a 44% coverage scenario across 18 prioritized provinces, subsequently expanding to achieve 100% coverage for all pregnant women in Indonesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.